Concomitant Hidradenitis Suppurativa and Pyoderma Gangrenosum – Adalimumab Biosimilar can Help: A Case Report

Abstract

Abstract Introduction: Systemic inflammation leading to various types of disorders with mainly cutaneous manifestations is not uncommon. Hidradenitis suppurativa (HS) and pyoderma gangrenosum (PG) may be the consequences of such situation and develop concomitantly in a single patient. Case Presentation: We present herewith a case of HS along with PG which was managed with Adalimumab biosimilar. Discussion: HS and PG are both uncommon inflammatory skin conditions linked to systemic inflammatory disorders. Adalimumab, a tumor necrosis factor-alpha antagonist, is used to treat a variety of inflammatory disorders. Biosimilars are biologics that are extremely similar to an already-approved reference biological product but are produced by a distinct company. Several biosimilar variants of adalimumab have been developed and approved by regulatory authorities in various countries. They can be used as alternatives to the reference product, resulting in potential cost-savings and increased treatment accessibility. Conclusions: Biosimilars of adalimumab have an important role in the management of HS and PS considering their favorable outcome.